Diabetes drug may fight heart scarring in High-Risk patients

NCT ID NCT05367063

Completed Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether canagliflozin, a diabetes drug, can reduce scarring in the heart muscle of people with type 2 diabetes who are at high risk for heart problems. 45 participants were randomly assigned to take either canagliflozin or sitagliptin daily. Researchers used MRI scans to measure changes in heart fibrosis over time, aiming to understand how the drug might protect the heart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Canagliflozin (a diabetes drug) compared to sitagliptin
What this could lead to: If it works, this could show that canagliflozin helps reduce heart scarring, potentially lowering heart failure risk in people with diabetes.
What could go wrong: This is a small, early-phase study with only 45 participants, so results may not apply broadly. The effect on heart scarring is uncertain, and the drug may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR RISK TYPE 2 DIABETES

Contacts and locations

Locations

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.